A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Conditions

• Acute Myeloid Leukemia (AML)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Pevonedistat — DRUG
  Pevonedistat IV infusion.
• Venetoclax — DRUG
  Venetoclax tablets.
• Azacitidine — DRUG
  Azacitidine IV or SC injection.

Study Details

The main aim is to see how the combination of pevonedistat + venetoclax + azacitidine compares to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy. Participants will receive either pevonedistat + venetoclax + azacitidine or venetoclax + azacitidine in 28-day treatment cycles. Bone marrow samples (biopsy) will be collected throughout the study. Pevonedistat will be given as an intravenous (IV) infusion and Azacitidine will be given through IV or subcutaneous (under the skin). Study treatments may continue as long as the participant is receiving benefit from it. Participants may choose to stop treatment at any time.

Key Dates

First listed

Feb 12, 2020

Start date

Oct 13, 2020

Status verified

Aug 2026

Primary completion

Sep 6, 2022

Completion

Oct 6, 2025

Study Design

Enrollment

164 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Venetoclax + Azacitidine
  Participants received venetoclax 100 milligram (mg) tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Days 3 through 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Days 1 through 21 or 28 as per Investigator's discretion. In addition, participants received azacitidine 75 milligrams per square meter (mg/m\^2) intravenous (IV) or subcutaneous (SC) dosing on Days 1 through 7 or Days 1 through 5, 8, and 9 in each cycle.
• Experimental: Pevonedistat + Venetoclax + Azacitidine
  Participants received pevonedistat 20 mg/m\^2 as a 60-minute IV infusion on Days 1, 3, and 5 in each 28-day cycle. In addition participants received venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Days 3 through 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Day 1 through 21 or 28 as per Investigator's discretion. Participants also received azacitidine 75 mg/m\^2 IV or SC dosing on Days 1 through 7 or Days 1 through 5, 8, and 9 in each cycle.

Primary Outcome Measure

Event-Free Survival (EFS) [ Time Frame: Up to 22 months ]

Locations (23)

Find similar trials in Gilbert, AZ

Related Studies

• Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
  PHASE2 · Recruiting · Bio-Path Holdings, Inc. · Los Angeles, California
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
  PHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Niclosamide in Pediatric Patients With Relapsed and Refractory AML
  PHASE1 · Recruiting · Stanford University · Palo Alto, California
• A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
  PHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey